Smoking history and underlying lung disease are associated with poor outcome in patients developing interstitial pneumonia during low-dose amiodarone therapy

Smoking history and underlying lung disease are associated with poor outcome in patients developing interstitial pneumonia during low-dose amiodarone therapy

Abstract Background Amiodarone is a useful antiarrhythmic drug, especially in patients with serious heart diseases, but amiodarone-induced interstitial pneumonia (AMD-IP) is sometimes lethal. Methods and results We retrospectively analyzed the clinical characteristics of 280 patients who were treate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of arrhythmia 2013-02, Vol.29 (1), p.5-8
Hauptverfasser: Nozoe, Masatsugu, MD, PhD, Honda, Toshihiro, MD, PhD, Honda, Mitsuko, MD, PhD, Ichikado, Kazuya, MD, PhD, Suga, Moritaka, MD, PhD, Nakao, Koichi, MD, PhD
Format: Artikel
Sprache:eng
Schlagworte:
Amiodarone
Analysis
Antiarrhythmics
Bacterial pneumonia
Body mass index
Cardiac arrhythmia
Cardiac patients
Cardiomyopathy
Cardiovascular
Cardiovascular diseases
Chronic obstructive pulmonary disease
Drug dosages
Ejection fraction
Evaluation
Interstitial pneumonia
Ischemia
Liver
Lung diseases
Lung diseases, Obstructive
Medical prognosis
Patient outcomes
Patients
Pneumonia
Pulmonary fibrosis
Regression analysis
Respiratory failure
Smoking
Steroids
Thyroid gland
Toxicity
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Amiodarone is a useful antiarrhythmic drug, especially in patients with serious heart diseases, but amiodarone-induced interstitial pneumonia (AMD-IP) is sometimes lethal. Methods and results We retrospectively analyzed the clinical characteristics of 280 patients who were treated with daily oral amiodarone. Among the patients, 29 (10.2%) developed AMD-IP during the follow-up period of 66.0±38.2 months. The average dose of amiodarone in the AMD-IP group (173±10 mg) was significantly higher than that in the non-AMD-IP group (150±3 mg). The prevalence of smoking history (AMD-IP group: 70.0%; non-AMD-IP group: 42.2%; P
ISSN:1880-4276
1883-2148
DOI:10.1016/j.joa.2012.04.005